Pharmasum Therapeutics AS is a private Norwegian specialty pharmaceutical company focused on the discovery and development of differentiated drugs for the treatment of autoimmune / metabolic and neurological diseases.

Founded in 2014 on the spin-out of industrial research on protein kinases, Pharmasum has offices in Tromsø and Oslo in Norway, and representation in the UK and USA. 

The company has an experienced management, board and international team of advisors.

About us | Management team

Anders Fugelli, PhD

Chairman and Chief Executive Officer

Anders Fugelli is Co-founder of Pharmasum Therapeutics. He has a passion for brain diseases, with more than 20 years’ experience in academia and industrial R&D. He comes from a role as Head of Business Development in Norwegian start-up pharmaceuticals company Lytix Biopharma and has worked as Partner of life sciences and technology advisors, Amino AS. During the merger of GlaxoWellcome and SmithKlineBeecham, Anders was responsible, as Worldwide Assistant Director of Clinical Development and Product Strategy, of bringing together an overall company approach to the migraine field of the Neurology teams.

Anders received his BSc (hons) from Imperial College, London, and PhD in neuropharmacology from the University of London (Imperial College) for work carried out at the Institute Pasteur, Paris and the Department of Preclinical Medical Sciences, Oslo. He also has additional training in corporate finance from the London Business School.

Anders Fugelli is a Norwegian citizen.

John Sigurd Svendsen, PhD

Chief Scientific Officer

John Sigurd Svendsen brings extensive research experience from work in medical biochemistry, synthetic organic chemistry and medicinal chemistry. He is a co-founder of the company and serves as its Chief Scientific Officer. Previously, he was Head of the exploratory research in Lytix Biopharma. John received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø.

John Sigurd Svendsen is a Norwegian citizen.

Pauline Stewart-Long, PhD

Head of Project Management

Pauline Stewart-Long is a biochemist by training and started her career in the Pharmaceutical industry conducting clinical trials in several therapeutic areas, notably cardiovascular, metabolic and neuroscience.  She has more than 20 years’ broad experience in pharmaceutical R&D project & portfolio management, initially managing projects and then as a Portfolio Director she established portfolio and project management in the GSK Respiratory CEDD.  As VP in GSK Global Project Management, Pauline was accountable for the practices, processes and tools covering all stages of discovery and development and providing highly capable project managers to all therapy areas. She is currently Director of Stewart-Long Solutions Ltd and assisting a number of companies as an independent advisor to develop their project management capability appropriately alongside business growth.

Pauline Stewart-Long is a British citizen.

Stig Jarle Pettersen, MSc

Chief Financial Officer

Stig Jarle Pettersen is engaged as CFO. He is a state authorized public accountant (Norway) educated from NHH, Norwegian School of Economics. He has worked as CFO in listed and private companies in Norway and Denmark and has broad experience from the pharmaceutical and biotech industry. In the last 4 years, he has worked as CFO for a portfolio of smaller R&D companies in the biotech and medtech sector.

Stig Jarle Pettersen is a Norwegian citizen.

Wenche Marie Olsen, PhD

Vice President Operations

Wenche Marie Olsen has extensive operational experience from drug development in large (Nycomed) and small pharma (Lauras AS, Lytix Biopharma AS). She received her PhD in biochemistry from the University of Oslo.

Wenche Marie Olsen is a Norwegian citizen.

About us | Board of directors

Anders Fugelli, PhD

Chairman and Chief Executive Officer

Anders Fugelli is Co-founder of Pharmasum Therapeutics. He has a passion for brain diseases, with more than 20 years’ experience in academia and industrial R&D. He comes from a role as Head of Business Development in Norwegian start-up pharmaceuticals company Lytix Biopharma and has worked as Partner of life sciences and technology advisors, Amino AS. During the merger of GlaxoWellcome and SmithKlineBeecham, Anders was responsible, as Worldwide Assistant Director of Clinical Development and Product Strategy, of bringing together an overall company approach to the migraine field of the Neurology teams.

Anders received his BSc (hons) from Imperial College, London, and PhD in neuropharmacology from the University of London (Imperial College) for work carried out at the Institut Pasteur, Paris and the Department of Preclinical Medical Sciences, Oslo. He also has additional training in corporate finance from the London Business School.

Anders Fugelli is a Norwegian citizen.

Øystein Soug, MSc

Director

Øystein Soug is CEO of Targovax ASA, a listed Norwegian biotech company. He is the former CFO of Algeta ASA which was sold to Bayer AG for USD 2.9 billion in 2014. Prior to joining Algeta in 2008 Mr Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division. Mr Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. He received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997.

Øystein Soug is a Norwegian citizen.

John Sigurd Svendsen, PhD

Chief Scientific Officer

John Sigurd Svendsen brings extensive research experience from work in medical biochemistry, synthetic organic chemistry and medicinal chemistry. He is a co-founder of the company and serves as its Chief Scientific Officer. Previously, he was Head of the exploratory research in Lytix Biopharma. John received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø.

John Sigurd Svendsen is a Norwegian citizen.

Reijo Salonen, MD, PhD

Director

Dr. Salonen holds a PhD in neuroimmunology from Turku University and an MD with specialization in neurology from Turku University in Finland.

Dr. Salonen has held senior positions in major pharmaceutical companies, serving as VP of Clinical Development and Product Strategy at GSK Neurology / GI, Global Head of Neurosciences Development at Pfizer and as Chief Medical Officer and SVP R&D at Orion Pharma. 

Reijo Salonen is a dual Finnish and US citizen.

Team expertise
Uli Hacksell, PhD

Uli holds a PhD organic chemistry from Uppsala University, Sweden.

He has held senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion-dollar company. 

Martin Lunnon, PhD

Translational Medicine: Martin has more than 35 years’ experience in translational medicine. He has formerly worked for GSK and Sanofi and has lead projects of more than 30 NMEs into man.

Rod Porter, PhD

Development chemistry: Rod is an experienced medicinal chemist, and was formerly with GSK.

Allison Morgan, PhD

Regulatory/clinical: Allison is an experienced orphan disease specialist, and was formerly with Prosensa.

Jeffrey Sprouse, PhD

Pharmacology: Jeffrey has over 20 years’ pharma R&D experience. He led projects in circadian rhythm modulation at Pfizer and Lundbeck.

Nigel Toseland, PhD

Tox / Safety: Nigel has over 30 years’ experience in preclinical tox/safety at GSK.